Comparative Pharmacology
Head-to-head clinical analysis: ERYC 125 versus PEDIAMYCIN 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC 125 versus PEDIAMYCIN 400.
ERYC 125 vs PEDIAMYCIN 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
400 mg orally every 6 hours for 10 days.
None Documented
None Documented
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic